Oregon Public Employees Retirement Fund Purchases New Shares in Hims & Hers Health, Inc. (NYSE:HIMS)

Oregon Public Employees Retirement Fund purchased a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 45,000 shares of the company’s stock, valued at approximately $1,088,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Crewe Advisors LLC purchased a new stake in Hims & Hers Health in the 4th quarter valued at $28,000. Raleigh Capital Management Inc. raised its position in Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 1,100 shares during the last quarter. Venturi Wealth Management LLC purchased a new stake in Hims & Hers Health in the 4th quarter valued at $48,000. GAMMA Investing LLC raised its position in Hims & Hers Health by 2,173.7% during the 4th quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after buying an additional 2,152 shares during the last quarter. Finally, Principal Securities Inc. raised its position in Hims & Hers Health by 48.2% during the 4th quarter. Principal Securities Inc. now owns 3,079 shares of the company’s stock worth $74,000 after buying an additional 1,002 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Soleil Boughton sold 268,932 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the sale, the insider now directly owns 169,803 shares of the company’s stock, valued at $4,712,033.25. This trade represents a 61.30 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Andrew Dudum sold 33,513 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $33.38, for a total transaction of $1,118,663.94. Following the sale, the chief executive officer now directly owns 33,502 shares in the company, valued at $1,118,296.76. This represents a 50.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,097,578 shares of company stock valued at $38,080,320 in the last ninety days. Insiders own 17.71% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on HIMS shares. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. TD Cowen restated a “buy” rating and set a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Morgan Stanley downgraded shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and upped their price objective for the stock from $42.00 to $60.00 in a research report on Tuesday, February 18th. Needham & Company LLC upped their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th. Finally, Citigroup upped their price objective on shares of Hims & Hers Health from $25.00 to $27.00 and gave the stock a “sell” rating in a research report on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $37.23.

Hims & Hers Health Trading Up 9.3 %

Shares of NYSE HIMS opened at $45.20 on Friday. The stock has a market cap of $10.04 billion, a price-to-earnings ratio of 102.72 and a beta of 1.35. Hims & Hers Health, Inc. has a 52 week low of $11.20 and a 52 week high of $72.98. The company’s 50-day moving average price is $36.57 and its 200 day moving average price is $26.74.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. The firm had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. As a group, research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.